Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

Bryan T. Kelly, Viengneesee Thao, Timothy M. Dempsey, Lindsey R. Sangaralingham, Stephanie R. Payne, Taylor T. Teague, Teng Moua, Nilay D. Shah, Andrew H. Limper

Research output: Contribution to journalArticlepeer-review


Background: Idiopathic Pulmonary Fibrosis is a chronic, progressive interstitial lung disease for which there is no cure. However, lung function decline, hospitalizations, and mortality may be reduced with the use of the antifibrotic medications, nintedanib and pirfenidone. Historical outcomes for hospitalized patients with Idiopathic Pulmonary Fibrosis are grim; however there is a paucity of data since the approval of nintedanib and pirfenidone for treatment. In this study, we aimed to determine the effect of nintedanib and pirfenidone on mortality following respiratory-related hospitalizations, intensive care unit (ICU) admission, and mechanical ventilation. Methods: Using a large U.S. insurance database, we created a one-to-one propensity score matched cohort of patients with idiopathic pulmonary fibrosis treated and untreated with an antifibrotic who underwent respiratory-related hospitalization between January 1, 2015 and December 31, 2018. Mortality was evaluated at 30 days and end of follow-up (up to 2 years). Subgroup analyses were performed for all patients receiving treatment in an ICU and those receiving invasive and non-invasive mechanical ventilation during the index hospitalization. Results: Antifibrotics were not observed to effect utilization of mechanical ventilation or ICU treatment during the index admission or effect mortality at 30-days. If patients survived hospitalization, mortality was reduced in the treated cohort compared to the untreated cohort when followed up to two years (20.1% vs 47.8%). Conclusions: Treatment with antifibrotic medications does not appear to directly improve 30-day mortality during or after respiratory-related hospitalizations. Post-hospital discharge, however, ongoing antifibrotic treatment was associated with improved long-term survival.

Original languageEnglish (US)
Article number239
JournalBMC Pulmonary Medicine
Issue number1
StatePublished - Dec 2021


  • Antifibrotics
  • Critical care
  • Hospitalization
  • Idiopathic pulmonary fibrosis
  • Mechanical ventilation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications'. Together they form a unique fingerprint.

Cite this